www.tcrt.org Dual-modality imaging is an in vivo diagnostic technique that obtains structural and functional information directly from patient studies in a way that cannot be achieved with separate imaging systems alone. Dual-modality imaging systems are configured by combining computed tomography (CT) with radionuclide imaging (using positron emission tomography (PET) or single-photon emission computed tomography (SPECT)) on a single gantry which allows both functional and structural imaging to be performed during a single imaging session without having the patient leave the imaging system. A SPECT/CT system developed at UCSF is being used in a study to determine if dual-modality imaging offers advantages for assessment of patients with prostate cancer using 111 In-ProstaScint ® , a radiolabeled antibody for the prostate-specific membrane antigen. 111 In-ProstaScint ® images are reconstructed using an iterative maximum-likelihood expectation-maximization (ML-EM) algorithm with correction for photon attenuation using a patient-specific map of attenuation coefficients derived from CT. The ML-EM algorithm accounts for the dual-photon nature of the 111 In-labeled radionuclide, and incorporates correction for the geometric response of the radionuclide collimator. The radionuclide image then can be coregistered and overlaid in color on a grayscale CT image for improved localization of the functional information from SPECT. Radionuclide images obtained with SPECT/CT and reconstructed using ML-EM with correction for photon attenuation and collimator response improve image quality in comparison to conventional radionuclide images obtained with filtered backprojection reconstruction. These results illustrate the potential advantages of dual-modality imaging for improving the quality and the localization of radionuclide uptake for staging disease, planning treatment, and monitoring therapeutic response in patients with cancer.
Introduction
Assessment of cancer often relies on measurement of tissue metabolism, tissue perfusion, receptor density, and other functional parameters that can be performed with radionuclide-tracer techniques. In vivo measurements can be performed using imaging techniques such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT). However, radionuclide imaging often lacks anatomical cues that are needed to localize or stage the disease. Radionuclide images also are produced with poorer statistical and spatial characteristics than anatomical imaging methods such as computed tomography (CT) and magnetic resonance imaging (MRI). In a clinical setting, both structural and functional information is needed to evaluate the status of the patient. However, the techniques used to assess anatomical structure (e.g., CT, MRI) typically are different than those used to assess function (e.g., PET, SPECT), and the structural and functional images generally are acquired in separate patient studies, often on different days. Therefore, the clinician must rely on his or her expertise and training to relate features in the structural image to those in the functional image to interpret the data. However, the visual correlation of these features is inexact and may be difficult to interpret.
The challenges of correlating structural and functional image data have motivated the development of new software approaches which combine MRI or CT with SPECT or PET to improve localization of radionuclide uptake and compensate for the inherent limitations of radionuclide imaging (1) (2) (3) (4) . Excellent work at many centers has developed image fusion methods that correlate functional information from SPECT or PET images with morphologic information from MRI or CT. For clinical use, these techniques are most successful for imaging the head, where the rigidity of the skull allows anatomical and physiological images to be fused using coordinate transformations applied in software. The situation is more complex when trying to correlate functional and structural images in the thorax or abdomen (5, 6); since the body can bend and flex, simple rigid body coordinate transformations are not easy to apply, especially when the two image sets are acquired on separate scanners over two different imaging sessions.
To facilitate the process of correlating structural and functional information, investigators at UCSF (7-9) and at the University of Pittsburgh (10, 11), and elsewhere (12, 13) have developed a new class of diagnostic instrumentation that combines x-ray CT and radionuclide imaging with SPECT or PET. These "dual-modality" systems use separate detectors for x-ray and radionuclide imaging, with the detectors integrated on a common gantry to simplify patient handling, data acquisition, and coregistration of the CT and radionuclide image data (11, 13) . These systems aim to improve the diagnostic process in two different but complementary ways. First, the CT and radionuclide data are acquired with the patient in the same position to facilitate image correlation between the CT and SPECT or PET data. This makes it possible to produce a "fused image" in which the radionuclide distribution can be displayed in color on a gray-scale CT image to coregister the anatomical and physiological features (11, 13) . Localization of the radionuclide distribution with CT in a dual-modality image therefore has the potential to improve evaluation of disease, in comparison to interpretation of disease with SPECT or PET alone.
In addition to correlating structural and functional information in the radionuclide and x-ray images, dual-modality imaging also provides another benefit, that of providing a priori anatomical information that can be used to improve the visual quality of radionuclide images obtained with SPECT or PET. When physiological function is assessed with conventional radionuclide imaging, the resulting images can be compromised by the spatial resolution and photon-statistical limitations of the radionuclide data and by the need for attenuation correction and scatter compensation (14, 15) . Specifically, when radionuclide images are acquired, gamma-rays emitted by the radionuclide distribution in the body are absorbed by overlying structures in the patient. Clinical SPECT and PET systems now are equipped with apparatus to acquire transmission scans of the patient with external radionuclide sources (16) (17) (18) (19) . The transmission data are reconstructed to generate a patient-specific map of attenuation coefficients for attenuation correction of the radionuclide image. This technique is used to improve the quality of myocardial perfusion imaging (20, 21) , but also has potential applications when radiopharmaceuticals are used for diagnosis and treatment of cancer. However, the resulting transmission scans do not have adequate image quality to delineate anatomical structure in the patient.
In this manuscript, we describe the use of a combined SPECT/CT system developed at the UCSF Physics Research Laboratory (8, 9, 22) . This work is an outgrowth of earlier prototype dual-modality systems developed at UCSF used to image animals and phantoms (23-26). However, the SPECT/CT system was configured to evaluate clinical applications of dual-modality imaging. In this manuscript, we describe early results from a study in which the SPECT/CT system is used to image patients with prostate cancer using 111 In-ProstaScint ® (Cytogen, Inc., Princeton, NJ), a radiolabeled antibody for the prostate-specific membrane antigen (27) . We describe both the configuration of the SPECT/CT system and the implementation of data correction, tomographic reconstruction, and image registration methods. We also present image data illustrating improvements in image quality that are available from this technique in comparison to conventional radionuclide imaging methods.
Materials and Methods
In this study, we use a dual-modality imaging system (8, 22) configured (with support from GE Medical Systems) from adjoining commercial x-ray CT and SPECT scanners. The system ( Fig. 1) is installed in a dedicated imaging room at the UCSF Physics Research Laboratory and allows both radionuclide and x-ray CT images to be acquired during a single imaging session. The radionuclide image is obtained using a GE 600 XR/T scintillation camera with a large rectangular field of view (approximately 400 mm × 500 mm). SPECT images are acquired as 128 × 128 image matrices using a 360º circular orbit with 64 stops at 60 s/stop for a total acquisition time of approximately 1 hour. For 111 In-ProstaScint ® , radionuclide data are acquired as a merged data set that combines counts from a 15% window at 171 keV and a 20% window at 245 keV.
The SPECT images are reconstructed with a filtered backprojection algorithm (28). The SPECT images also are recon-structed using an iterative reconstruction algorithm under 3 different conditions: (i) no attenuation correction with 30 iterations of an iterative maximum-likelihood expectation-maximization (ML-EM) algorithm (29, 30) (described below), (ii) including attenuation correction with 30 iterations of an ML-EM algorithm, and (iii) using 100 iterations of an ML-EM algorithm that incorporates corrections for both photon attenuation and the geometric response of the collimator, following reconstruction parameters optimized in phantom studies (31).
CT images are obtained with a GE 9800 Quick CT scanner using a standard pelvic technique (140 kVp, 120 mA, 3 s scans, 256 × 256 image matrix, 48 cm reconstruction diameter, 5 mm slice thickness, 5 mm slice spacing) and are reconstructed using filtered-backprojection software and standard reconstruction filters provided by the manufacturer. Correlated CT and radionuclide scans are acquired by translating the patient from one detector to the other while the patient remains on the patient table (8, 22) . This allows the CT and radionuclide images to be acquired with a consistent scanner geometry and body habitus, and with minimal delay between the two acquisitions.
Attenuation Correction
Radionuclide imaging is compromised by physical effects that introduce perturbations that affect both the visual quality and the quantitative accuracy of the radionuclide image. One such perturbation is caused by photon attenuation in which gamma-rays emitted by the radiopharmaceutical distribution in the body are absorbed by overlying body tissues. This can reduce the image intensity in areas of radiopharmaceutical uptake that correspond to disease, and can introduce nonuniformities in which the intensity of the radionuclide image is reduced in central regions of the body, and is enhanced in the periphery. These photon attenuation errors can be compensated by incorporating a model of the photon attenuation process into the reconstruction algorithm (20, 21, (32) (33) (34) (35) (36) . The attenuation correction methods require that the operator has an estimate of the patient-specific distribution of attenuation coefficients representing photon attenuation in the region of the body being imaged. This is commonly performed using SPECT and PET systems by using an external radionuclide source to acquire transmission scans patient at multiple angles around the body. The transmission data then are reconstructed to generate a map of attenuation coefficients for each location in the patient's body. Alternatively, CT scans can be acquired and reconstructed to generate a map of attenuation coefficients for the region of the body being imaged using a CT-derived attenuation map (37-41). Whether they are acquired with an external radionuclide source, or with an x-ray tube in a CT scanner, the transmission data generally are measured at a photon energy different than that used to acquire the radionuclide data. In this case, calibration measurements must be performed that allows the acquired transmission data to be reconstructed and calibrated to produce an attenuation map at the energy of the emission data (38). In the SPECT/CT system, the attenuation map is calibrated using measurements from a phantom with cylindrical inserts containing water, fat-equivalent (ethanol) and bone-equivalent (K 2 HPO 4 ) materials, and iodinated contrast agents. CT numbers extracted from each region are plotted against their known attenuation coefficients at the photon energy of the radionuclide to provide a piece-wise linear calibration curve (9, 22) . The resulting curve is used to calibrate a subsequent CT scan of the patient to generate an object-specific attenuation map that is incorporated into an iterative maximum-likelihood expectation-maximization (ML-EM) algorithm to reconstruct the radionuclide data. These techniques have been tested extensively in SPECT/CT studies on phantoms (22, 42), animals (9, 25), and humans (8, 27) .
Attenuation Correction of 111 In-labeled Radiopharmaceuticals
In this manuscript, we present SPECT/CT images of 111 In-ProstaScint ® , a radiolabeled antibody used for diagnosis of patients with prostate cancer (43). Unlike most single photon radiopharmaceuticals that emit photons of a single energy (e.g., 99m Tc, 123 I) or within a limited energy range (e.g., 210 Tl), 111 In has two distinct gamma emissions (171.3 keV and 245.4 keV) of roughly equal intensities (90.2% and 94.0% respectively). Because the physical perturbations affecting SPECT (attenuation, scatter, and to a lesser extent, camera resolution) are energy dependent, any compensation for these effects must take into account the dual-energy nature of the 111 In photon emission. As discussed in the pre-vious section, attenuation maps for each photon energy can be derived from CT to correct radionuclide data for photon attenuation.
However, in a clinical setting 111 In-ProstaScint ® images typically are reconstructed without attenuation correction. A method of fully accounting for the dual-energy nature of the 111 In photon emission would treat the two emissions separately in the reconstruction algorithm, and would require two reconstruction operations (one for each energy), but this procedure is time-consuming and rarely is applied in a clinical setting.
Recently, Wong et al. (27) have developed a technique that accounts for the dual-photon nature of 111 In emission with a relatively simple procedure that requires only one rather than two reconstruction operations. This technique models the emission of a dual-energy radionuclide like 111 In and determines whether the attenuation of the intensities of the photons of both energies can be expressed by a single "equivalent" attenuation coefficient µ eff. The unattenuated photon intensities (I 01 , I 02 ) recorded in the absence of any absorption caused by overlying body tissues are related to the photon intensities (I 1 , I 2 ) measured by the SPECT system in the presence of soft tissue attenuation for the two photon energies E 1 and E 2 respectively,
For a water-equivalent attenuation length of x = 20 cm (corresponding to a typical patient is about 40 cm), Wong, et al. (27) have shown that the effective attenuation coefficient has a value of µ eff = 0.135 cm -1 . Furthermore, the value of µ eff changes by only 0.9% over a range of tissue thicknesses from 1 to 40 cm, making this value relatively insensitive to variations in patient thickness. Therefore, the dual-photon data from 111 In can be acquired in a single energy window and reconstructed with attenuation correction using the value of µ eff described above.
Collimator Response
Errors contributed by photon attenuation are exacerbated by other physical effects inherent to the imaging process. In gamma-ray scintigraphy and SPECT, these errors include spatial resolution limitations introduced by the geometry of the parallel hole collimator (44, 45) used to acquire the radionuclide data, which creates an inherent trade-off in spatial resolution and sensitivity. That is, the bores of the parallel hole collimator can be configured with a wider aperture diameter or with a shorter bore length to improve the geometric efficiency of the collimator while degrading spatial resolution. Conversely, if the collimator is made with a narrower bore diameter and a longer bore length, then the spatial resolution improves with a corresponding loss in geometric efficiency. In this way, the geometry and corresponding response of the collimator are important factors which limit the spatial resolution and geometric efficiency of the SPECT system.
The geometry of the imaging system can be compensated in the reconstruction algorithm by incorporating an accurate "projector", a set of mathematical equations that models the geometry of the imaging system. Conventional reconstruction algorithms assume that gamma-rays strike the detector perpendicular to its surface in a way that does not account for the divergent gamma-ray paths that occur with realistic radionuclide collimators. Several investigators (8, 36, 46) have developed techniques that account for realistic collimator characteristics by incorporating projectors that more accurately model the geometrical response of the collimator.
In this study, we implemented a method that models the depth-dependent spatial resolution of the radionuclide imaging device (8, 47) . The algorithm parameterizes the geometric response, or point spread function (PSF), of a given collimator, measured experimentally using a radionuclide point source at various distances from the detector surface.
Image Reconstruction
Radionuclide images can be reconstructed using analytic methods such as filtered backprojection. However, as described above, the radionuclide data contain errors contributed by physical effects such as photon attenuation, collimator response, and scattered radiation that are not accounted for in these reconstruction techniques. For this reason, radionuclide images in this study were reconstructed using iterative methods that account for the statistical nature of the radionuclide data, and that can include an accurate projector model that accounts for both photon attenuation and the geometric response of the collimator. The specific algorithm used in this study was the well-known maximum-likelihood expectation-maximization (ML-EM) algorithm (29, 30) In Eq.
[2], λ refers to a voxel in the reconstructed SPECT image for iteration k. The indices b and b´ have values from 1 to N b which enumerate all voxels in the reconstructed image. The index d has values 1 to N d and enumerates all of the pixels in the projection data, where n´(d) is the number of counts measured in the d th detector pixel. The probability function p (b,d) represents the likelihood that a photon emitted from object voxel b is detected at detector pixel d, and thereby contains information about the geometry of the imaging system including the collimator design, the charac- 
teristics of the detector used to acquire the radionuclide data from the object, and the physical characteristics of the object including photon attenuation that affect the acquisition process. The image reconstruction begins with an estimate of the patient radionuclide distribution (λ k (b´)) generally assumed to be uniform within the reconstruction circle of the imaging system for all values of b. Eq.
[2] then mathematically projects the radionuclide distribution onto the detector using the properties of the probability function p(b´,d) and compares the results with the experimentally measured projection data n´(d). The algorithm then calculates a correction term that is used to update the estimated image data so that a new iterative estimate can be calculated.
Image Registration and Image Fusion
A critical benefit of SPECT/CT and other dual-modality imaging techniques is that radionuclide and anatomical images are acquired with a consistent scanner geometry and body habitus, and with minimal delay between the two image data sets (8, 10, 11, 13, 22, 48) . This occurs because the two scanners are fixed relative to one another and function as an integrated system with a common patient table. X-ray CT scans and radionuclide scans are acquired in succession via a simple translation of the imaging table, minimizing registration uncertainty due to patient repositioning and shifts in internal anatomy. As an aid to image registration, patients are imaged by placing fiducial markers on the patient table and on the patient's surface to provide a common set of coordinates for the SPECT and CT systems (31). The fiducial markers contain a small volume (0.2 ml) of a solution containing 300 mg/ml of K 2 HPO 4 that can be visualized with CT, and 33 µCi/ml of 99m Tc that can be visualized with SPECT. After the images are acquired, they are reviewed by an observer who identifies the approximate centers of the fiducial markers on both the CT and SPECT images. A computer program has been developed to calculate the centroid of the markers based on the pixel values in both the CT and SPECT images (31). The measured coordinates of the markers then are used to derive a transformation matrix that translates, rotates, and magnifies the coordinates of the SPECT image so that they match corresponding points in the CT image. The transformed SPECT data are reformatted so that they have the same image matrix size, slice thickness, and pixel dimensions as the original CT image to account for differences in scanner geometry and image format (e.g., 128 × 128 vs. 512 × 512) between the two data sets. Our phantom experiments (31) have demonstrated that our image registration technique is accurate to well within one pixel for both the standard reconstructed x-ray CT images (0.94 mm for a 512 × 512 large field-of-view CT image) and reconstructed radionuclide images (4.32 mm for 128 × 128 images). In patient images, registration errors are dominated by the thickness of the CT slice (typically 5-10 mm) and by gross patient motion that occurs during the imaging procedure (31). Once the SPECT and CT coordinate systems are registered as described above, image fusion then can be performed with in-house software that displays the radionuclide data in color superimposed on a grayscale CT image.
Patient Recruitment and Handling
In this manuscript, we present image data from a patient enrolled in a study on human volunteers with the goal of demonstrating that SPECT/CT improves the sensitivity and specificity of assessments of prostate cancer with 111 In-ProstaScint ® in comparison to results from SPECT alone (27, 31) . Patients enrolled in this study are required to meet the normal indications for a 111 In-ProstaScint ® study; they must have or be suspected of having prostate cancer with a relatively high risk for lymph node metastases or have rising PSA after radical prostatectomy. Any patient who is unable to give free and informed consent is excluded. Additional exclusion factors include patient size or body habitus that would make CT or nuclear imaging impossible (e.g., patients over 350 pounds) and patients who are allergic to shellfish or iodine, or have had previous allergic reactions to radiographic contrast media. All patients enrolled in this study sign an informed consent form approved by the institutional review board at UCSF.
Imaging Protocol
For the imaging study, the patient receives a standard intravenous dose of 111 In-ProstaScint ® (0.5 mg of capromab pendetide radiolabeled with approximately 5 mCi of 111 In) at the Nuclear Medicine Clinic at UCSF. On Day 4 following injection, the patient returns to UCSF for a clinical 111 In-ProstaScint ® scan and then visits the UCSF Physics Research Laboratory for imaging with SPECT/CT (27, 31) . For the SPECT/CT scan, four or more markers (as described above) are placed on the patient to help assess patient motion and to aid in registration of the CT and nuclear images. CT imaging does not use nonionic contrast media following the normal procedure for patients undergoing CT for radiation oncology treatment planning. In addition, imaging with contrast media changes the contrast characteristics of the CT image, making it more difficult to utilize the CT data to reconstruct an attenuation map that can be used to correct the radionuclide image data for photon attenuation. The patient is imaged with x-ray CT over the extent of the abdomen and pelvis. The patient then is translated into the adjoining scintillation camera for SPECT imaging of the abdomen and pelvis. All radionuclide images are acquired with a parallel hole medium-energy collimator.
After acquisition, radionuclide images are reconstructed using conventional filtered backprojection and with a maximum-likelihood expectation-maximization (ML-EM) algo-rithm as described above. Images from both the SPECT/CT system and from SPECT alone (i.e., conventional scintigraphy without a priori structural information from the coregistered CT image) are interpreted by nuclear medicine specialists for activity outside of the radiopharmaceutical's normal biodistribution, for increased activity in the prostatic fossa, and for abnormal activity outside the prostatic fossa (extraprostatic lesions). Unlike conventional radionuclide images, those from the SPECT/CT system are overlaid with the CT image for correlation of functional and anatomical information, following the procedure described above.
Results
Representative SPECT images from a patient undergoing 111 In-ProstaScint ® imaging are shown in Figure 2 . Figure 2a (left) was produced with a conventional filtered backprojection reconstruction algorithm. In comparison, Figure 2b (right) was produced with 30 iterations of an iterative reconstruction algorithm and is similar to those that would be produced by state-of-the-art SPECT systems in most medical centers, although many medical centers still use filtered backprojection reconstruction and would produce images of the quality shown in Figure 2a . The images shown in Figure  3 were reconstructed using iterative reconstruction incorpo-rating (a) an accurate model of collimator response and (b) an accurate model of collimator response and photon attenuation using a patient-specific map of attenuation coefficients derived from the correlated CT scan (31). The images shown in Figure 3 show a clear qualitative advantage in terms of noise and image detail in that 111 In-ProstaScint ® uptake in bone marrow delineates bony anatomy in the pelvis, in comparison to those shown in Figure 2 . The inclusion of attenuation correction eliminates extraneous pixel values outside of the patient's anatomy, and also reduces artificial enhancement of pixel values near the body surface. Figure 4 shows CT and combined SPECT/CT images of the same patient data shown in Figure 2 and Figure 3 . The SPECT image reconstructed with corrections for both collimator response and photon attenuation contains an abnormal bright spot in the upper right quadrant of the patient, identified by the arrow in Figure 3b . Other regions of enhanced uptake in Figure 3b correspond to regions with normal nonspecific uptake of 111 In-ProstaScint ® . The corresponding CT image (Fig. 4a ) provides anatomical information in which the bony anatomy of the pelvis is visualized clearly, along with other internal structures including both fluidfilled and air-filled regions of the bowel. Qualitatively, the bright spot in the upper right quadrant of Figure 3b corresponds to a loop of bowel that can be visualized with CT (Fig. 4a) , a common area for nonspecific uptake of 111 In-ProstaScint ® . This impression is confirmed by inspecting the overlay image, in which the 111 In-ProstaScint ® uptake is displayed in red over the CT image. In this case, the information provided by the SPECT/CT system was helpful in ruling out the presence of disease, whereas the SPECT information by itself would have provided equivocal results.
Discussion
The diagnosis and staging of many cancers now relies on modern imaging techniques such as computed tomography, (Fig. 3b ) reconstructed with an ML-EM algorithm with corrections for photon attenuation and for the geometric response of the radionuclide collimator, superposed on the correlated CT image (Fig. 4a ). magnetic resonance imaging, positron emission tomography, and single-photon emission computed tomography (49). In comparison to surgical techniques or biopsy, medical imaging has advantages for this task in that it is noninvasive and can cover relatively large areas of the patient anatomy. In most cases, medical imaging is not definitive for ruling out the presence of cancer, especially in the case of small or lowgrade lesions which are below the resolution or sensitivity capabilities of the imaging system. However, imaging can identify and localize lesions associated with the primary tumor or metastatic disease in a way that is crucial for patient management including screening, staging, treatment planning, and therapeutic monitoring (49).
Many cancers, including those of the lung, brain, breast, and others, can be assessed using metabolic agents, most notably 18 F-fluorodeoxyglucose ( 18 FDG) imaged with positron emission tomography (PET) or with coincidence imaging using a dual-detector scintillation camera. However, 18 FDG has some important limitations for imaging other cancers, including those of the prostate. Normal prostate cells have high glucose utilization and 18 FDG is excreted primarily via the bladder which is located superior to the prostate (50). These two effects make it very difficult to assess abnormal 18 FDG uptake in the region of the prostate and to identify cancer cells definitively. 18 FDG-PET is not helpful in the evaluation of organ-confined prostate cancer (51, 52), but can be very useful in locating distant metastatic disease (53), especially when PSA is high (54).
Therefore, patients with elevated serum PSA at risk for disseminated disease, or patients with elevated PSA following prostatectomy at risk for residual disease (43) can be imaged with 111 In-ProstaScint ® (capromab pendetide) using planar scintigraphy or more commonly with SPECT. 111 In-ProstaScint ® is an antibody for the prostate-specific membrane antigen (PMSA), a protein similar to prostate specific antigen (PSA), but generally is bound to the cell membrane rather than being shed into the bloodstream like PSA. PSMA generally is expressed at some level in all prostate tissues, but is present in greater numbers in prostate cancer (55). Although imaging with 111 In-ProstaScint ® provides a unique biochemical window on the patient's prostate cancer, it also has significant limitations. 111 In-ProstaScint ® imaging is performed 4 to 5 days after the radiopharmaceutical is injected to allow the antibody time to label target tissues and to clear from background regions (56). As a consequence, the radiotracer is imaged at relatively low radioactivity levels and produces images that are photon-starved and noisy. In addition, 111 In-ProstaScint ® studies usually are acquired in concert with a blood pool image using 99m Tc-labeled redblood cells to identify major blood vessels and other anatomical cues needed to interpret the 111 In-ProstaScint ® data. However, even with anatomical markers in the blood pool and the 111 In-ProstaScint ® images, it even can be difficult to identify the prostate and other important structures in the body. There also is significant nonspecific uptake of 111 In-ProstaScint ® in the bowel and liver that can complicate interpretation of the image. Activity in the pubic bone marrow and rectum (57) may be difficult to distinguish from activity emanating from the prostatic fossa using SPECT alone. Furthermore, bowel activity can lead to false-positive interpretations of lymphatic involvement (58, 59) . Anatomical interpretation of pelvic 111 In-ProstaScint ® SPECT data can be difficult because of its limited ability to accurately localize focal uptake.
The SPECT/CT system described in this manuscript can help overcome the difficulties in interpreting 111 In-ProstaScint ® images by providing coregistered CT images of the pelvis with excellent presentation of anatomical structures. The improved localization capabilities of the SPECT/CT system are enhanced by improvements in the visual quality obtained from radionuclide images reconstructed using corrections for photon attenuation and collimator response, as shown in Figure 3 . We have not yet completed a clinical study to test whether 111 In-ProstaScint ® imaging with SPECT/CT improves the observer's ability to differentiate uptake in normal structures from uptake in tumor, or to localize radionuclide uptake in tumors, in comparison to conventional imaging. However, the data presented in this study provide qualitative evidence of these advantages in a way that would be useful for both diagnostic interpretation of the radionuclide images, as well as the use of correlated SPECT/CT imaging for treatment planning and therapeutic monitoring of the patient with prostate cancer.
While the SPECT/CT system used for this study is a prototype instrument available only at our institution, it is important to note that GE Medical Systems (Milwaukee WI) and Elgems Ltd (Haifa Israel) now have developed a similar dualmodality imaging system that combines SPECT and CT. Radionuclide imaging is performed with two rectangular scintillation cameras with NaI(Tl) crystals mounted on a slip ring to perform radionuclide tomography (12, 13) . The system can be operated with conventional collimators for planar scintigraphy or SPECT, and also performs coincidence detection of annihilation photons for imaging 18 F-fluorodeoxyglucose ( 18 FDG) and other positron-emitting radionuclides. The system can perform low-resolution CT with a separate x-ray tube and detector mounted on the same gantry. The resulting anatomical images are generated with a spatial resolution of 2.5 mm FWHM in plane and with a 1 cm mid-plane slice width. The CT image can be used for anatomical localization of the radionuclide data, and also can be calibrated to the energy of the radionuclide photon for attenuation correction of the radionuclide image. Transmission scanning is obtained with a scan time of approximately 20 sec per slice with a 40-cm diameter axial field of view for both radionuclide and xray imaging. This system (GE Discovery VH or "Hawkeye") recently has been installed for clinical use in the Nuclear Medicine Program at UCSF and also is being used or is scheduled for installation at approximately 200 other nuclear medicine departments world-wide.
In addition, at the University of Pittsburgh, Townsend, Beyer, and Kinahan (10, 11, 40) implemented a combined PET/CT ("SMART") system by combining an ECAT ART PET system from CTI Incorporated with a Somatom AR.SP spiral CT scanner from Siemens Medical Systems. Patient studies with PET/CT at the University of Pittsburgh and at other institutions have demonstrated improved correlation of functional and anatomical information when images of radionuclide uptake are fused with the correlated CT image (10). More recently, several PET/CT scanners have been developed or are under development by commercial vendors for clinical utilization including those by GE Medical Systems, Siemens Medical Systems, CTI, Incorporated, and by Philips Nuclear Medicine Systems (formerly ADAC Laboratories). These commercial dual-modality imaging systems now are being incorporated for clinical studies world-wide, especially those involving cancer. Other dualmodality imaging systems are under development for functional and structural imaging of rodents and other small animals (60-68) involved in biological experimentation, pharmaceutical development, and developments in the biotechnology industry. It therefore appears that the ability of dualmodality imaging to correlate structure and function in a direct way has advantages both in clinical medicine and in experimental science, in a way that especially applicable for cancer research, diagnosis, and treatment.
